



NOV 20 2000



TECH CENTER 1600/2200

Patent Docket P1101P1

UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Application of Ashkenazi et al. Serial No.: 09/020,746 Filed: February 9, 1998 For: Apo-2 Receptor</p>	<p>Group Art Unit: 1646 Examiner: L. Spector</p> <hr/> <p><b>CERTIFICATE OF MAILING</b> I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on</p> <p>November 9, 2000 <i>Diane L. Marschang</i> Diane L. Marschang</p>
---	---

*C/22*  
*11/21/00*  
*(W.E.)*  
*ok*  
*to enter*  
*11/30/00*  
*[Signature]*

**AMENDMENT**

Box AF  
Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

This paper is being filed in response to the Office Action mailed May 12, 2000. Entry of the following amendments and consideration of the remarks herein are respectfully requested.

**IN THE CLAIMS:**

Please cancel claims 19 and 20 without prejudice.

21. (Amended) A monoclonal antibody which (a) binds to Apo-2 polypeptide [comprising] consisting of the contiguous amino acid residues 1 to 411 of SEQ ID NO:1 and (b) stimulates apoptosis in at least one type of mammalian cell in vivo or ex vivo.

*C1 4A*  
22. (Amended) A monoclonal antibody which (a) binds to a soluble [polypeptide comprising an] extracellular domain sequence of an [native sequence] Apo-2 polypeptide which [comprises] consists of amino acids 54 to 182 of SEQ ID NO:1 and (b) stimulates apoptosis in at least one type

85

C